Compounds > mk 767
Page last updated: 2024-09-04

mk 767 and 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide

mk 767 has been researched along with 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide in 1 studies

Compound Research Comparison

Studies
(mk 767)		Trials
(mk 767)		Recent Studies (post-2010)
(mk 767)		Studies
(4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide)		Trials
(4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide)		Recent Studies (post-2010) (4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide)
320101008

Protein Interaction Comparison

ProteinTaxonomymk 767 (IC50)4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide (IC50)
Tyrosine-protein kinase LckHomo sapiens (human)0.0002
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.002
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)1.83
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.001
Tyrosine-protein kinase SYKHomo sapiens (human)0.292
Mitogen-activated protein kinase 8Homo sapiens (human)0.389
Mitogen-activated protein kinase 9Homo sapiens (human)0.173
Tyrosine-protein kinase JAK3Homo sapiens (human)0.072
Mitogen-activated protein kinase 10Homo sapiens (human)0.145
Tyrosine-protein kinase BTKHomo sapiens (human)0.545
Mitogen-activated protein kinase 14Homo sapiens (human)0.003

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1

Other Studies

1 other study(ies) available for mk 767 and 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013